Houston professor earns Google Scholar award for quantum computing research

recent recognition

A Rice University quantum computer scientist was one of 78 global professors to be presented with a 2023 Google Scholar award, the university announced this month.

Nai-Hui Chia, an assistant professor of computer science at Rice, was recognized for his research on Hamiltonian simulations, a method for representing the motion of moving particles. Chia aims to understand if quantum computers or machines can simulate a "Hamiltonian matrix" with a shorter evolution time.

"We call this fast-forwarding for a Hamiltonian simulation,” Chia says in a statement.

Chia aims to use the funds from Google to discover Hamiltonians that can be fast-forwarded using parallelism or classical computation, according to Rice. He will present his current work on Hamiltonians and their connection to cryptology in July at the 2023 Computational Complexity Conference in Warwick, UK.

The Google Research Scholar program grants funds of up to $60,000 to support professors' research around the world. This year's cohort works in fields ranging from algorithms and optimization to natural language processing to health research.

Three other Texas researchers were awarded funds in the 2023 cohort.

The University of Texas at Austin's Jon Tamir was awarded for his work in applied sciences. Atlas Wang, also from UT, was awarded in the machine learning and data mining category. Shenglong Xu, from Texas A&M University, joined Chia in the quantum computing category.

Tech behemoth Google has awarded funds to several Houston innovators in recent years.

Last summer the company named AnswerBite, Boxes and Ease to its inaugural cohort of the Google for Startups Latino Founders Fund. Selected companies received an equity-free $100,000 investment, as well as programming and support from Google.

In September 2022, ChurchSpace and Enrichly were named part of the Google for Startups Black Founders Fund. The companies also received $100,000 non-dilutive awards along with mentoring and support.

From Your Site Articles

The new endowment will be available beginning in fall 2020. University of Texas at Austin/Facebook

University of Texas at Austin to provide free tuition to families making less than $65,000

higher ed

The University of Texas at Austin is taking a big step to combat the increasing costs of higher education. On July 9, the system's Board of Regents voted to establish a $160 million endowment to help Texas families ease the burden of funding a UT education.

Beginning in fall 2020, the endowment will cover in-state tuition and fees for students from families that earn up to $65,000 a year, or about 8,600 undergraduates a year. (Texas' median income was $59,206 in 2017, according to the most recent available numbers.)

Under the current Texas Advance Commitment, full tuition is only provided to families earning up to $30,000 per year.

Along with covering costs for families making $65,000 or less, the new endowment will provide "tuition support" for families making $125,000 or less, or about 5,700 students.

The $160 million endowment is a distribution of the state's Permanent University Fund, which "includes money from oil and gas royalties earned on state-owned land in West Texas," according to a release.

"There is no greater engine of social and economic mobility than a college degree, and this initiative ensures that more Texans will benefit from a high-quality UT Austin education," said Chancellor James B. Milliken, in a release.

The decision is undoubtedly a banner one for UT President Gregory Fenves, who has spent the majority of his tenure working on affordability issues. In a release, Fenves echoed Milliken, calling the fund an "invest[ment] in the future of our great state."

"I am grateful to the UT System Board of Regents and Chairman Kevin Eltife for prioritizing students and investing in the future of our great state," said Fenves. "This new endowment will go a long way toward making our university affordable for talented Texas students from every background and region."

------

This story originally appeared on CultureMap.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

3 Houston startups named most innovative in Texas by LexisNexis

report card

Three Houston companies claimed spots on LexisNexis's 10 Most Innovative Startups in Texas report, with two working in the geothermal energy space.

Sage Geosystems claimed the No. 3 spot on the list, and Fervo Energy followed closely behind at No. 5. Fintech unicorn HighRadius rounded out the list of Houston companies at No. 8.

LexisNexis Intellectual Property Solutions compiled the report. It was based on each company's Patent Asset Index, a proprietary metric from LexisNexis that identifies the strength and value of each company’s patent assets based on factors such as patent quality, geographic scope and size of the portfolio.

Houston tied with Austin, each with three companies represented on the list. Caris Life Sciences, a biotechnology company based in Dallas, claimed the top spot with a Patent Asset Index more than 5 times that of its next competitor, Apptronik, an Austin-based AI-powered humanoid robotics company.

“Texas has always been fertile ground for bold entrepreneurs, and these innovative startups carry that tradition forward with strong businesses based on outstanding patent assets,” Marco Richter, senior director of IP analytics and strategy for LexisNexis Intellectual Property Solutions, said in a release. “These companies have proven their innovation by creating the most valuable patent portfolios in a state that’s known for game-changing inventions and cutting-edge technologies.We are pleased to recognize Texas’ most innovative startups for turning their ideas into patented innovations and look forward to watching them scale, disrupt, and thrive on the foundation they’ve laid today.”

This year's list reflects a range in location and industry. Here's the full list of LexisNexis' 10 Most Innovative Startups in Texas, ranked by patent portfolios.

Caris (Dallas)
Apptronik (Austin)
Sage Geosystems (Houston)
HiddenLayer (Austin)
Fervo Energy (Houston)
Plus One Robotics (San Antonio)
Diligent Robotics (Austin)
HighRadius (Houston)
LTK (Dallas)
Eagle Eye Networks (Austin)

Sage Geosystems has partnered on major geothermal projects with the United States Department of Defense's Defense Innovation Unit, the U.S. Air Force and Meta Platforms. Sage's 3-megawatt commercial EarthStore geothermal energy storage facility in Christine, Texas, was expected to be completed by the end of last year.

Fervo Energy fully contracted its flagship 500 MW geothermal development, Cape Station, this spring. Cape Station is currently one of the world’s largest enhanced geothermal systems (EGS) developments, and the station will begin to deliver electricity to the grid in 2026. The company was recently named North American Company of the Year by research and consulting firm Cleantech Group and came in at No. 6 on Time magazine and Statista’s list of America’s Top GreenTech Companies of 2025. It's now considered a unicorn, meaning its valuation as a private company has surpassed $1 billion.

Meanwhile, HighRadius announced earlier this year that it plans to release a fully autonomous finance platform for the "office of the CFO" by 2027. The company reached unicorn status in 2020.

---

This article originally appeared on Energy Capital HTX.

UH student earns prestigious award for cancer vaccine research

up-and-comer

Cole Woody, a biology major in the College of Natural Sciences and Mathematics at the University of Houston, has been awarded a Barry Goldwater Scholarship, becoming the first sophomore in UH history to earn the prestigious prize for research in natural sciences, mathematics and engineering.

Woody was recognized for his research on developing potential cancer vaccines through chimeric RNAs. The work specifically investigates how a vaccine can more aggressively target cancers.

Woody developed the MHCole Pipeline, a bioinformatic tool that predicts peptide-HLA binding affinities with nearly 100 percent improvement in data processing efficiency. The MHCole Pipeline aims to find cancer-specific targets and develop personalized vaccines. Woody is also a junior research associate at the UH Sequencing Core and works in Dr. Steven Hsesheng Lin’s lab at MD Anderson Cancer Center.

“Cole’s work ethic and dedication are unmatched,” Preethi Gunaratne, director of the UH Sequencing Core and professor of Biology & Biochemistry at NSM, said in a news release. “He consistently worked 60 to 70 hours a week, committing himself to learning new techniques and coding the MHCole pipeline.”

Woody plans to earn his MD-PhD and has been accepted into the Harvard/MIT MD-PhD Early Access to Research Training (HEART) program. According to UH, recipients of the Goldwater Scholarship often go on to win various nationally prestigious awards.

"Cole’s ability to independently design and implement such a transformative tool at such an early stage in his career demonstrates his exceptional technical acumen and creative problem-solving skills, which should go a long way towards a promising career in immuno-oncology,” Gunaratne added in the release.

Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME